Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022116 (ischemia)
 91,303 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Stroke is one of the leading causes of death in the United States. The risk of experiencing a recurrent stroke remains elevated for several years after an initial stroke or a transient ischemic attack (TIA), therefore secondary prevention is crucial in reducing the risk of stroke and the complications and costs associated with stroke. Aggrenox, a combination of low-dose aspirin and extended-release dipyridamole, is a new agent that is effective in the secondary prevention of stroke and transient ischemia of the brain. The clinical effect of its two antiplatelet agents are additive and significantly better than either aspirin or dipyridamole alone, although it has not been shown to be more effective than aspirin alone in preventing death. Aggrenox is much more expensive than aspirin alone but has been shown to be more cost-effective. At this point, much of the pharmacologic information concerning this combination agent is based on previous data about aspirin and immediate-release dipyridamole. This combination of aspirin and extended-release dipyridamole may play a significant role in secondary stroke and TIA prevention.
 ...
PMID:Aggrenox: an aspirin and extended-release dipyridamole combination. 1197 16

This article reviews the current use of antiplatelet medications in secondary stroke prevention and in acute stroke treatment. Antiplatelet medications prevent emboli and thrombus formation to avert further vascular occlusion and ischemia. Aspirin, clopidogrel (Plavix), and extended release aspirin/dipyridamole (Aggrenox) represent the mainstay of secondary prevention of ischemic and transient ischemic stroke. Although antiplatelet medications prevent platelet aggregation by different mechanisms, the end result is a significantly decreased risk of secondary stroke, myocardial infarction, and death. Increasingly, the literature reflects hypotheses about the potential utility of aspirin and clopidogrel antiplatelet therapy as a preventative measure in patients at risk of stroke and as an approach to treat embolic ischemic stroke in the acute phase once it has occurred.
 ...
PMID:Antiplatelets and stroke outcomes: state of the science. 1995 67